Biotech | October 13, 2021
Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Investment demonstrates confidence in America’s commitment to science and innovation
Delivers robust earnings performance, successfully navigating a dynamic environment
Bayer expects 2025 to be the most difficult year of its turnaround
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Subscribe To Our Newsletter & Stay Updated
